| A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants (NCT06151535) | AbbVie | 2023-12-19 |
| A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (NCT06118411) | AbbVie | 2023-12-19 |
| A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants (NCT06174688) | AbbVie | 2023-12-12 |
| A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease (NCT05995353) | AbbVie | 2023-12-11 |
| Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting (NCT05956483) | AbbVie | 2023-12-04 |
| An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease (NCT05916157) | AbbVie | 2023-11-30 |
| A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295 (NCT06144684) | AbbVie | 2023-11-29 |
| A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants (NCT06137287) | AbbVie | 2023-11-22 |
| ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars (NCT05995340) | AbbVie | 2023-11-21 |
| A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults (NCT06054425) | AbbVie | 2023-11-20 |
| A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. (NCT06063967) | AbbVie | 2023-11-15 |
| Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (NCT06068868) | AbbVie | 2023-11-13 |
| Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab (NCT06107413) | AbbVie | 2023-11-12 |
| Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 (NCT06084481) | AbbVie | 2023-11-09 |
| An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO) (NCT05959070) | AbbVie | 2023-11-09 |
| Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis. (NCT05782907) | AbbVie | 2023-11-06 |
| A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain (NCT06125795) | AbbVie | 2023-11-06 |
| A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer (NCT06068842) | AbbVie | 2023-11-03 |
| Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant (NCT05978622) | AbbVie | 2023-10-30 |
| An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK) (NCT06126146) | AbbVie | 2023-10-26 |
| A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants (NCT06068855) | AbbVie | 2023-10-17 |
| A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (NCT06012240) | AbbVie | 2023-10-11 |
| Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine (NCT05748483) | AbbVie | 2023-10-07 |
| A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants (NCT06070948) | AbbVie | 2023-10-05 |
| Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. (NCT05609630) | AbbVie | 2023-10-02 |
| Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants (NCT06067568) | AbbVie | 2023-09-28 |
| Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (NCT05822752) | AbbVie | 2023-09-21 |
| Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy (NCT06150729) | AbbVie | 2023-09-08 |
| A Study to Assess Adverse Events and Effectiveness of HAC 20L Injections in Adult Participants for the Treatment of Nasolabial Folds (NCT06018987) | AbbVie | 2023-09-05 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD) (NCT06024239) | AbbVie | 2023-08-31 |
| A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants (NCT06009237) | AbbVie | 2023-08-23 |
| A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration (NCT05995366) | AbbVie | 2023-08-18 |
| Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis (NCT05959083) | AbbVie | 2023-08-18 |
| Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis (NCT05969223) | AbbVie | 2023-08-10 |
| A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder (NCT05941442) | AbbVie | 2023-07-31 |
| Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (NCT05843643) | AbbVie | 2023-07-25 |
| A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function (NCT05940402) | AbbVie | 2023-07-24 |
| Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine (NCT05861427) | AbbVie | 2023-07-12 |
| Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers (NCT05892757) | AbbVie | 2023-07-11 |
| A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine (NCT05935033) | AbbVie | 2023-06-30 |
| A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants (NCT05878067) | AbbVie | 2023-06-27 |
| An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants (NCT05827887) | AbbVie | 2023-06-25 |
| A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers (NCT05895266) | AbbVie | 2023-06-23 |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (NCT05889182) | AbbVie | 2023-06-21 |
| Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers (NCT05909553) | AbbVie | 2023-06-15 |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (NCT05814627) | AbbVie | 2023-06-15 |
| A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants (NCT05818709) | AbbVie | 2023-06-14 |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (NCT05753501) | AbbVie | 2023-06-09 |
| An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD) (NCT05841537) | AbbVie | 2023-06-09 |
| A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan (NCT06362044) | AbbVie | 2023-06-07 |
| Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine (NCT05707949) | AbbVie | 2023-06-05 |
| A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review (NCT06362031) | AbbVie | 2023-06-01 |
| A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis (NCT05507580) | AbbVie | 2023-05-29 |
| A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine (NCT05711394) | AbbVie | 2023-05-01 |
| A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide (NCT05760313) | AbbVie | 2023-04-27 |
| A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) (NCT05512390) | AbbVie | 2023-04-26 |
| Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis (NCT05785715) | AbbVie | 2023-04-24 |
| A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants (NCT05836506) | AbbVie | 2023-04-18 |
| A Study to Assess Adverse Events and Effectiveness of Injected JUVÉDERM® VOLITE™ Gel Filler for Change in Neck Lines in Adult Chinese Participants (NCT05741034) | AbbVie | 2023-04-07 |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets (NCT05618028) | AbbVie | 2023-04-04 |
| A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma (NCT05650632) | AbbVie | 2023-03-21 |
| Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis (NCT05570006) | AbbVie | 2023-03-16 |
| Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (NCT05445778) | AbbVie | 2023-03-15 |
| An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World (NCT05669794) | AbbVie | 2023-02-21 |
| Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants (NCT05738850) | AbbVie | 2023-02-15 |
| Effect of Long-term Psoriasis on Patients' Life - CORONATE (NCT05555953) | AbbVie | 2023-01-26 |
| A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants (NCT05686980) | AbbVie | 2023-01-17 |
| First in Human Study of IMGN151 in Recurrent Gynaecological Cancers (NCT05527184) | AbbVie | 2023-01-11 |
| Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy (NCT05158894) | AbbVie | 2023-01-10 |
| A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections (NCT05647551) | AbbVie | 2023-01-05 |
| A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults (NCT05691699) | AbbVie | 2023-01-03 |
| A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (NCT05652205) | AbbVie | 2022-12-29 |
| An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Japan (NCT05791526) | AbbVie | 2022-12-19 |
| An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants (NCT05653986) | AbbVie | 2022-12-18 |
| A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom (NCT05555979) | AbbVie | 2022-12-14 |
| A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib (NCT05451316) | AbbVie | 2022-12-08 |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (NCT05599984) | AbbVie | 2022-12-05 |
| A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease (NCT05644977) | AbbVie | 2022-12-02 |
| A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (NCT05601882) | AbbVie | 2022-11-28 |
| A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT05513703) | AbbVie | 2022-11-21 |
| An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA) (NCT05411211) | AbbVie | 2022-11-10 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma (NCT05259839) | AbbVie | 2022-10-20 |
| Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis (NCT05496348) | AbbVie | 2022-10-20 |
| Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants (NCT05556226) | AbbVie | 2022-10-18 |
| Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers. (NCT05567029) | AbbVie | 2022-09-28 |
| Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer (NCT05456685) | AbbVie | 2022-09-28 |
| A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor (NCT05538585) | AbbVie | 2022-09-27 |
| A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis (NCT05530278) | AbbVie | 2022-09-20 |
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada (NCT05424562) | AbbVie | 2022-09-07 |
| A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around the Mouth (NCT05454033) | AbbVie | 2022-09-07 |
| A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia (NCT05443724) | AbbVie | 2022-09-02 |
| A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines (NCT05496335) | AbbVie | 2022-08-30 |
| A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review (NCT05444972) | AbbVie | 2022-08-23 |
| Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia (NCT05368558) | AbbVie | 2022-08-18 |
| A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease (NCT05291234) | AbbVie | 2022-08-15 |
| An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice (NCT05494606) | AbbVie | 2022-08-15 |
| Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants (NCT05475821) | AbbVie | 2022-07-25 |
| Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma (NCT05411198) | AbbVie | 2022-07-22 |
| Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD (NCT05439616) | AbbVie | 2022-07-07 |
| A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis (NCT05414201) | AbbVie | 2022-07-07 |